摘要
目的:观察慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期脾肾阳虚证患者应用喘可治注射液治疗的临床疗效。方法:选择2014年3月期间在医院诊治的118例的COPD稳定期脾肾阳虚证患者,随机分为实验组60例和对照组58例,两组患者均给予常规治疗,实验组给予喘可治注射液治疗,每日1次,疗程12周,比较两组患者肺功能、生活质量和预后,定期随访9个月。结果:3个月后,实验组FEV1、FEV1/FVC、MVV均显著高于对照组(P<0.05)。实验组躯体功能、心理功能、社会功能、特异模块、总分及Barthel指数评分均显著高于对照组(P<0.05)。9个月内,实验组COPD急性发作发生率均显著低于对照组(P<0.05)。结论:喘可治注射液治疗COPD稳定期脾肾阳虚证患者有良好的临床疗效,值得推广。
Objective： This dissertation aims to observe the clinical efficacy of Chuankezhi Injection in the treatment of chronic obstructive pulmonary disease（ COPD） of spleen- kidney deficiency syndrome in stable phase. Methods： In March 2014,118 cases in our hospital with Spleen- Kidney Deficiency syndrome of COPD in stable phase were randomly divided into the experimental group 58 cases and the control group 60 cases. Two groups were given general treatment.The experimental group was given Chuankezhi Injection,once a day for 12 weeks. We compared lung function,quality of life and prognosis of the two groups,regular follow- up for nine months. Results： Three months later,the experimental group＇s FEV1,FEV1 / FVC and MVV were significantly higher（ P 〈0. 05）. Experimental physical function,psychological function,social function,specific modules,score and Barthel Index scores were significantly higher（ P 〈0. 05）. Within nine months,the occurrence of acute exacerbation of COPD in the experimental group was significantly lower than that of the control group（ P 〈0. 05）. Conclusion： Chuankezhi Injection treating COPD patients of spleen- kidney deficiency syndrome in stable phase has good clinical efficacy,worthy of promotion.
出处
《中华中医药学刊》
CAS
北大核心
2016年第1期57-59,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金青年科学基金项目(81302935)
